Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

AAIPharma Acquires Cvitkovic & Associes Consultants

  • AAIPharma reported a definitive agreement to acquire Cvitkovic & Associes Consultants (CAC), an international contract research organization specializing in oncology drug development and medical consulting. The acquisition of CAC provides AAIPharma with additional therapeutic expertise and strengthens its global clinical development business. The acquisition is expected to close in the fourth quarter of 2006.

    CAC has 10 years of experience in performing lead assessment of new analogues of established drugs, as well as novel target-oriented compounds. The company’s knowledge in cancer therapies includes cytotoxics, cytostatics, Mabs, cell-based therapies, vaccines, antiangiogenic agents, apoptosis inducers, and hormonal therapies.

    CAC brings to AAIPharma specialized, full-service capabilities in the early stages of oncology drug development, as well as in conducting large international Phase IIb/III studies.

    “Having established our own model of clinical CRO services, based on therapeutic specificity combined with medical and scientific know-how, CAC has now reached the limits of its organic growth,” explains Esteban Cvitkovic, CAC chairman and founder.

    CAC is headquartered in Paris and has offices in the U.S., Europe, and Latin America.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »